- Home
- INMB vs CLLS Comparison
INMB vs CLLS Comparison
Compare INMB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | CLLS |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 299.0M |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | INMB | CLLS |
|---|---|---|
| Price | $2.03 | $4.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.30 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 507.4K | 146.6K |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $50,000.00 | ★ $82,551,000.00 |
| Revenue This Year | $173.21 | $32.58 |
| Revenue Next Year | $12,733.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.05 | ★ 129.04 |
| 52 Week Low | $1.38 | $1.10 |
| 52 Week High | $11.64 | $5.48 |
Technical Indicators
Market Signals| Indicator | INMB | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 53.17 |
| Support Level | $1.54 | $4.47 |
| Resistance Level | $2.30 | $5.45 |
| Average True Range (ATR) | 0.16 | 0.30 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 65.48 | 20.41 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.